Critical analysis in the advancement of cell-based assays for botulinum neurotoxin

References

• Adler S, Bicker G, Bigalke H, Bishop C, Blümel J, Dressler D, Fitzgerald J, Gessler F, Heuschen H, Kegel B, et al. 2010. The current scientific and legal status of alternative methods to the LD50 test for botulinum neurotoxin potency testing. The report and recommendations of a ZEBET Expert Meeting. Altern Lab Anim. 38(4):315–330.
   PubMed Web of Science ®Google Scholar
• Ahsan CR, Hajnóczky G, Maksymowych AB, Simpson LL. 2005. Visualization of binding and transcytosis of botulinum toxin by human intestinal epithelial cells. J Pharmacol Exp Ther. 315(3):1028–1035.
   PubMed Web of Science ®Google Scholar
• Akaike N, Ito Y, Shin M-C, Nonaka K, Torii Y, Harakawa T, Ginnaga A, Kozaki S, Kaji R. 2010. Effects of A2 type botulinum toxin on spontaneous miniature and evoked transmitter release from the rat spinal excitatory and inhibitory synapses. Toxicon. 56(8):1315–1326.
   PubMed Web of Science ®Google Scholar
• Arango MT, Quintero-Ronderos P, Castiblanco J, Montoya-Ortíz G, et al. 2013. Cell culture and cell analysis. In: Anaya JM, Shoenfeld Y, Rojas-Villarraga A, editors. Autoimmunity: from bench to bedside [Internet]. Bogota (Colombia): El Rosario University Press. Chapter 45. https://www.ncbi.nlm.nih.gov/books/NBK459464.
   Google Scholar
• Arnon SS, Schechter R, Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Fine AD, Hauer J, Layton M, Working Group on Civilian Biodefense, et al. 2001. Botulinum toxin as a biological weapon: medical and public health management. JAMA. 285(8):1059–1070.
   PubMed Web of Science ®Google Scholar
• Auguet M, Favre-Guilmard C, Cornet S, Carre D, Rocher MN, Pignol B, Pham B, Chabrier PE. 2013. Effects of botulinum toxin type A on digit abduction score and running wheel assays and assessment of diffusion using calcium-activated potassium channel expression. Toxicon. 68:82.
   Web of Science ®Google Scholar
• Babrak L, Lin A, Stanker L, McGarvey J, Hnasko R. 2016. Rapid microfluidic assay for the detection of botulinum neurotoxin in animal sera. Toxins. 8(1):13.
   PubMed Web of Science ®Google Scholar
• Bagramyan K, Barash JR, Arnon SS, Kalkum M. 2008. Attomolar detection of botulinum toxin type A in complex biological matrices. PLOS One. 3(4):e2041.
   PubMed Web of Science ®Google Scholar
• Bang S, Lee B-J, Lee S-R, Na S, Jang JM, Kang M, Kim S-Y, Min D-H, Song JM, Ho W-K, et al. 2018. Reliable autapse formation using the single-cell patterning method. Biofabrication. 11(1):015008.
   PubMed Web of Science ®Google Scholar
• Barash JR, Arnon SS. 2014. A novel strain of Clostridium botulinum that produces type B and type H botulinum toxins. J Infect Dis. 209(2):183–191
   PubMed Web of Science ®Google Scholar
• Benatar MG, Willison HJ, Vincent A. 1997. Lack of effect of Miller Fisher sera/plasmas on transmitter release from PC12 cells. J Neuroimmunol. 80(1–2):1–5.
   PubMed Web of Science ®Google Scholar
• Bercsenyi K, Giribaldi F, Schiavo G. 2013. The elusive compass of clostridial neurotoxins: deciding when and where to go? Curr Top Microbiol Immunol. 364:91–113.
   PubMed Web of Science ®Google Scholar
• Beske PH, Scheeler SM, Adler M, McNutt PM. 2015. Accelerated intoxication of GABAergic synapses by botulinum neurotoxin A disinhibits stem cell-derived neuron networks prior to network silencing. Front Cell Neurosci. 9:159.
   PubMed Web of Science ®Google Scholar
• Bigalke H, Rummel A. 2015. Botulinum neurotoxins: qualitative and quantitative analysis using the mouse phrenic nerve hemidiaphragm assay (MPN). Toxins. 7(12):4895–4905.
   PubMed Web of Science ®Google Scholar
• Bigalke H, Dreyer F, Bergey G. 1985. Botulinum A neurotoxin inhibits non-cholinergic synaptic transmission in mouse spinal cord neurons in culture. Brain Res. 360(1–2):318–324.
   PubMed Web of Science ®Google Scholar
• Bigalke H, Dimpfel W, Habermann E. 1978. Suppression of 3H-acetylcholine release from primary nerve cell cultures by tetanus and botulinum-A toxin. Naunyn Schmiedebergs Arch Pharmacol. 303(2):133–138.
   PubMed Web of Science ®Google Scholar
• Bitz S. 2010. The botulinum neurotoxin LD50 test – problems and solutions. ALTEX. 27(2):114–116.
   PubMedGoogle Scholar
• Blasi J, Chapman ER, Link E, Binz T, Yamasaki S, De Camilli P, Südhof TC, Niemann H, Jahn R. 1993. Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25. Nature. 365(6442):160–163.
   PubMed Web of Science ®Google Scholar
• Blum FC, Przedpelski A, Tepp WH, Johnson EA, Barbieri JT. 2014. Entry of a recombinant, full-length, atoxic tetanus neurotoxin into Neuro-2a cells. Infect Immun. 82(2):873–881.
   PubMed Web of Science ®Google Scholar
• Bonventre PF. 1979. Absorption of botulinal toxin from the gastrointestinal tract. Rev Infect Dis. 1(4):663–667.
   PubMedGoogle Scholar
• CDC 1998. Botulism in the United States, 1899--1996: handbook for epidemiologists, clinicians, and laboratory workers. Atlanta: US Department of Health and Human Services, CDC. http://www.cdc.gov/ncidod/dbmd/diseaseinfo.
   Google Scholar
• Chen S. 2012. Clinical uses of botulinum neurotoxins: current indications, limitations and future developments. Toxins. 4(10):913–939.
   Google Scholar
• Cherington M. 1998. Clinical spectrum of botulism. Muscle Nerve. 21(6):701–710.
   PubMed Web of Science ®Google Scholar
• Chipman PH, Zhang Y, Rafuse VF. 2014. A stem-cell based bioassay to critically assess the pathology of dysfunctional neuromuscular junctions. PLOS One. 9(3):e91643.
   PubMed Web of Science ®Google Scholar
• Couesnon A, Shimizu T, Popoff MR. 2009. Differential entry of botulinum neurotoxin A into neuronal and intestinal cells. Cell Microbiol. 11(2):289–308.
   PubMed Web of Science ®Google Scholar
• Couesnon A, Pereira Y, Popoff MR. 2008. Receptor-mediated transcytosis of botulinum neurotoxin A through intestinal cell monolayers. Cell Microbiol. 10(2):375–387.
   PubMed Web of Science ®Google Scholar
• Dong M, Tepp WH, Liu H, Johnson EA, Chapman ER. 2007. Mechanism of botulinum neurotoxin B and G entry into hippocampal neurons. J Cell Biol. 179(7):1511–1522.
   PubMed Web of Science ®Google Scholar
• Dong M, Yeh F, Tepp WH, Dean C, Johnson EA, Janz R, Chapman ER. 2006. SV2 is the protein receptor for botulinum neurotoxin A. Science. 312(5773):592–596.
   PubMed Web of Science ®Google Scholar
• Dong M, Richards DA, Goodnough MC, Tepp WH, Johnson EA, Chapman ER. 2003. Synaptotagmins I and II mediate entry of botulinum neurotoxin B into cells. J Cell Biol. 162(7):1293–1303.
   PubMed Web of Science ®Google Scholar
• Dong M, Tepp WH, Johnson EA, Chapman ER. 2004. Using fluorescent sensors to detect botulinum neurotoxin activity in vitro and in living cells. Proc Natl Acad Sci USA. 101(41):14701–14706.
   PubMed Web of Science ®Google Scholar
• Elias M, Al-Saleem F, Ancharski DM, Singh A, Nasser Z, Olson RM, Simpson LL. 2011. Evidence that botulinum toxin receptors on epithelial cells and neuronal cells are not identical: implications for development of a non-neurotropic vaccine. J Pharmacol Exp Ther. 336(3):605–612.
   PubMed Web of Science ®Google Scholar
• Evidente VG, Adler CH. 2010. An update on the neurologic applications of botulinum toxins. Curr Neurol Neurosci Rep. 10(5):338–344.
   PubMed Web of Science ®Google Scholar
• Fernandez-Salas E. 2012. Botulinum neurotoxin serotype A specific cell-based potency assay to replace the mouse bioassay. PLOS One. 7(11):e49516.
   PubMed Web of Science ®Google Scholar
• Foran PG, Mohammed N, Lisk GO, Nagwaney S, Lawrence GW, Johnson E, Smith L, Aoki KR, Dolly JO. 2003. Evaluation of the therapeutic usefulness of botulinum neurotoxin B, C1, E, and F compared with the long-lasting type A. Basis for distinct durations of inhibition of exocytosis in central neurons. J Biol Chem. 278(2):1363–1371.
   PubMed Web of Science ®Google Scholar
• Foster KA. 2016. Molecular aspects of botulinum neurotoxin. New York, NY: Springer.
   Google Scholar
• Frisk ML, Tepp WH, Johnson EA, Beebe DJ. 2009. Self-assembled peptide monolayers as a toxin sensing mechanism within arrayed microchannels. Anal Chem. 81(7):2760–2767.
   PubMed Web of Science ®Google Scholar
• Fujinaga Y, Inoue K, Nomura T, Sasaki J, Marvaud JC, Popoff MR, Kozaki S, Oguma K. 2000. Identification and characterization of functional subunits of Clostridium botulinum type A progenitor toxin involved in binding to intestinal microvilli and erythrocytes. FEBS Lett. 467(2–3):179–183.
   PubMed Web of Science ®Google Scholar
• Fujinaga Y, Inoue K, Watarai S, Sakaguchi Y, Arimitsu H, Lee J-C, Jin Y, Matsumura T, Kabumoto Y, Watanabe T, et al. 2004. Molecular characterization of binding subcomponents of Clostridium botulinum type C progenitor toxin for intestinal epithelial cells and erythrocytes. Microbiology. 150(Pt 5):1529–1538.
   PubMedGoogle Scholar
• Fujinaga Y, Inoue K, Watanabe S, Yokota K, Hirai Y, Nagamachi E, Oguma K. 1997. The haemagglutinin of Clostridium botulinum type C progenitor toxin plays an essential role in binding of toxin to the epithelial cells of guinea pig small intestine, leading to the efficient absorption of the toxin. Microbiology. 143(12):3841–3847.
   PubMedGoogle Scholar
• Fujinaga Y. 2010. Interaction of botulinum toxin with the epithelial barrier. J Biomed Biotechnol. 2010:974943.
   PubMedGoogle Scholar
• Ghosal KJ, Patel K, Singh BR, Hale ML. 2018. Role of critical elements in botulinum neurotoxin complex in toxin routing across intestinal and bronchial barriers. PLOS One. 13(7):e0199524.
   PubMed Web of Science ®Google Scholar
• Guo J, Xu C, Li X, Chen S. 2014. A simple, rapid and sensitive FRET assay for botulinum neurotoxin serotype B detection. PLOS One. 9(12):e114124.
   PubMed Web of Science ®Google Scholar
• Habermann E, Dreyer F, Bigalke H. 1980. Tetanus toxin blocks the neuromuscular transmission in vitro like botulinum A toxin. Naunyn Schmiedebergs Arch Pharmacol. 311(1):33–40.
   PubMed Web of Science ®Google Scholar
• Hamark C, Berntsson RP, Masuyer G, Henriksson LM, Gustafsson R, Stenmark P, Widmalm G. 2017. Glycans confer specificity to the recognition of ganglioside receptors by botulinum neurotoxin A. J Am Chem Soc. 139(1):218–230.
   PubMed Web of Science ®Google Scholar
• Han SW, Jang E, Koh W-G. 2015. Microfluidic-based multiplex immunoassay system integrated with an array of QD-encoded microbeads. Sens Actuators, B. 209:242–251.
   Web of Science ®Google Scholar
• Hatheway CL. 1995. Botulism: the present status of the disease. Curr Top Microbiol Immunol. 195:55–75.
   PubMed Web of Science ®Google Scholar
• Haubner F, Ohmann E, Müller-Vogt U, Kummer P, Strutz J, Gassner HG. 2012. Effects of botulinum toxin a on cytokine synthesis in a cell culture model of cutaneous scarring. Arch Facial Plast Surg. 14(2):122–126.
   PubMedGoogle Scholar
• Homann U, Thiel G. 1994. Cl- and K + channel currents during the action potential in Chara. Simultaneous recording of membrane voltage and patch currents. J Membr Biol. 141(3):297–309.
   PubMed Web of Science ®Google Scholar
• Hong WS, Young EWK, Tepp WH, Johnson EA, Beebe DJ. 2013. A microscale neuron and Schwann cell coculture model for increasing detection sensitivity of botulinum neurotoxin type A. Toxicol Sci. 134(1):64–72.
   PubMed Web of Science ®Google Scholar
• Hubbard K, Beske P, Lyman M, McNutt P. 2015. Functional evaluation of biological neurotoxins in networked cultures  of stem cell-derived central nervous system neurons. J Vis Exp. (96).DOI:10.3791/52361
   PubMed Web of Science ®Google Scholar
• Hubbard KS, Gut IM, Lyman ME, Tuznik KM, Mesngon MT, McNutt PM. 2012. High yield derivation of enriched glutamatergic neurons from suspension-cultured mouse ESCs for neurotoxicology research. BMC Neurosci. 13:127.
   PubMed Web of Science ®Google Scholar
• Inoue K, Fujinaga Y, Watanabe T, Ohyama T, Takeshi K, Moriishi K, Nakajima H, Inoue K, Oguma K. 1996. Molecular composition of Clostridium botulinum type A progenitor toxins. Infect Immun. 64(5):1589–1594.
   PubMed Web of Science ®Google Scholar
• Jin Y, Takegahara Y, Sugawara Y, Matsumura T, Fujinaga Y. 2009. Disruption of the epithelial barrier by botulinum haemagglutinin (HA) proteins – differences in cell tropism and the mechanism of action between HA proteins of types A or B, and HA proteins of type C. Microbiology. 155(Pt 1):35–45.
   PubMedGoogle Scholar
• Johnson EA, Montecucco C. 2008. Botulism. Handb Clin Neurol. 91:333–368.
   PubMedGoogle Scholar
• Jones RGA, Alsop T-A, Hull R, Tierney R, Rigsby P, Holley J, Sesardic D. 2006. Botulinum type A toxin neutralisation by specific IgG and its fragments: a comparison of mouse systemic toxicity and local flaccid paralysis assays. Toxicon. 48(3):246–254.
   PubMed Web of Science ®Google Scholar
• Kegel B, Behrensdorf-Nicol HA, Bonifas U, Silberbach K, Klimek J, Krämer B, Weißer K. 2007. An in vitro assay for detection of tetanus neurotoxin activity: using antibodies for recognizing the proteolytically generated cleavage product. Toxicol in Vitro. 21(8):1641–1649.
   PubMed Web of Science ®Google Scholar
• Keller JE, Cai F, Neale EA. 2004. Uptake of botulinum neurotoxin into cultured neurons. Biochemistry. 43(2):526–532.
   PubMed Web of Science ®Google Scholar
• Kiris E, Nuss JE, Burnett JC, Kota KP, Koh DC, Wanner LM, Torres-Melendez E, Gussio R, Tessarollo L, Bavari S. 2011. Embryonic stem cell-derived motoneurons provide a highly sensitive cell culture model for botulinum neurotoxin studies, with implications for high-throughput drug discovery. Stem Cell Res. 6(3):195–205.
   PubMed Web of Science ®Google Scholar
• Koga T, Kozaki S, Takahashi M. 2002. Exocytotic release of alanine from cultured cerebellar neurons. Brain Res. 952(2):282–289.
   PubMed Web of Science ®Google Scholar
• Kull S, Schulz KM, Weisemann J, Kirchner S, Schreiber T, Bollenbach A, Dabrowski PW, Nitsche A, Kalb SR, Dorner MB, et al. 2015. Isolation and functional characterization of the novel Clostridium botulinum neurotoxin A8 subtype. PLOS One. 10(2):e0116381.
   PubMed Web of Science ®Google Scholar
• Kumar R, Baisvar VS, Kushwaha B, Waikhom G, Singh M. 2019. Evolutionary analysis of genus Channa based on karyological and 16S rRNA sequence data. J Genet. 98(5):112
   Web of Science ®Google Scholar
• Kutschenko A, Weisemann J, Kollewe K, Fiedler T, Alvermann S, Böselt S, Escher C, Garde N, Gingele S, Kaehler S-B, et al. 2019. Botulinum neurotoxin serotype D – A potential treatment alternative for BoNT/A and B non-responding patients. Clin Neurophysiol. 130(6):1066–1073.
   PubMed Web of Science ®Google Scholar
• Lam K-H, Guo Z, Krez N, Matsui T, Perry K, Weisemann J, Rummel A, Bowen ME, Jin R. 2018. A viral-fusion-peptide-like molecular switch drives membrane insertion of botulinum neurotoxin A1. Nat Commun. 9(1):5367.
   PubMedGoogle Scholar
• Lam KH, Jin R. 2015. Architecture of the botulinum neurotoxin complex: a molecular machine for protection and delivery. Curr Opin Struct Biol. 31:89–95.
   PubMed Web of Science ®Google Scholar
• Lamanna C, Spero L, Schantz EJ. 1970. Dependence of time to death on molecular size of botulinum toxin. Infect Immun. 1(4):423–424.
   PubMedGoogle Scholar
• Lamanna C, Hillowalla RA, Alling CC. 1967. Buccal exposure to botulinal toxin. J Infect Dis. 117(4):327–331.
   PubMed Web of Science ®Google Scholar
• Lamotte JDD, Roqueviere S, Gautier H, Raban E, Bouré C, Fonfria E, Krupp J, Nicoleau C. 2021. hiPSC-derived neurons provide a robust and physiologically relevant in vitro platform to test botulinum neurotoxins. Front Pharmacol. 11:617867.
   PubMed Web of Science ®Google Scholar
• Lin L, Olson ME, Eubanks LM, Janda KD. 2019. Strategies to counteract botulinum neurotoxin A: nature's deadliest biomolecule. Acc Chem Res. 52(8):2322–2331.
   PubMed Web of Science ®Google Scholar
• Maksymowych AB, Simpson LL. 1998. Binding and transcytosis of botulinum neurotoxin by polarized human colon carcinoma cells. J Biol Chem. 273(34):21950–21957.
   PubMed Web of Science ®Google Scholar
• Maksymowych AB, Simpson LL. 2004. Structural features of the botulinum neurotoxin molecule that govern binding and transcytosis across polarized human intestinal epithelial cells. J Pharmacol Exp Ther. 310(2):633–641.
   PubMed Web of Science ®Google Scholar
• Maksymowych AB, Reinhard M, Malizio CJ, Goodnough MC, Johnson EA, Simpson LL. 1999. Pure botulinum neurotoxin is absorbed from the stomach and small intestine and produces peripheral neuromuscular blockade. Infect Immun. 67(9):4708–4712.
   PubMed Web of Science ®Google Scholar
• Matsumura T. 2008. The HA proteins of botulinum toxin disrupt intestinal epithelial intercellular junctions to increase toxin absorption. Cell Microbiol. 10(2):355–364.
   PubMed Web of Science ®Google Scholar
• McInnes C, Dolly JO. 1990. Ca2(+)-dependent noradrenaline release from permeabilised PC12 cells is blocked by botulinum neurotoxin A or its light chain. FEBS Lett. 261(2):323–326.
   PubMed Web of Science ®Google Scholar
• McNutt P, Beske P, Thirunavukkarsu N. 2015. Cell-based assays for neurotoxins. In: Gopalakrishnakone P, Balali-Mood M, Llewellyn L, Singh BR, editors. Biological toxins and bioterrorism toxinology. Dordrecht: Springer.
   Google Scholar
• McNutt P, Celver J, Hamilton T, Mesngon M. 2011. Embryonic stem cell-derived neurons are a novel, highly sensitive tissue culture platform for botulinum research. Biochem Biophys Res Commun. 405(1):85–90.
   PubMed Web of Science ®Google Scholar
• Montal M. 2010. Botulinum neurotoxin: a marvel of protein design. Annu Rev Biochem. 79:591–617.
   PubMed Web of Science ®Google Scholar
• Montecucco C. 1986. How do tetanus and botulinum toxins bind to neuronal membranes? Trends Biochem Sci. 11(8):314–317.
   Web of Science ®Google Scholar
• Montecucco C, Schiavo G. 1995. Structure and function of tetanus and botulinum neurotoxins. Q Rev Biophys. 28(4):423–472.
   PubMed Web of Science ®Google Scholar
• Montecucco C, Rasotto MB. 2015. On botulinum neurotoxin variability. mBio. 6(1). DOI:10.1128/mBio.02131-14
   PubMed Web of Science ®Google Scholar
• Munchau A, Bhatia KP. 2000. Uses of botulinum toxin injection in medicine today. BMJ. 320(7228):161–165.
   PubMedGoogle Scholar
• Nakamura T, Tonozuka T, Ide A, Yuzawa T, Oguma K, Nishikawa A. 2008. Sugar-binding sites of the HA1 subcomponent of Clostridium botulinum type C progenitor toxin. J Mol Biol. 376(3):854–867.
   PubMed Web of Science ®Google Scholar
• Nishiki T, Kamata Y, Nemoto Y, Omori A, Ito T, Takahashi M, Kozaki S. 1994. Identification of protein receptor for Clostridium botulinum type B neurotoxin in rat brain synaptosomes. J Biol Chem. 269(14):10498–10503.
   PubMed Web of Science ®Google Scholar
• Nuss JE, Ruthel G, Tressler LE, Wanner LM, Torres-Melendez E, Hale ML, Bavari S. 2010. Development of cell-based assays to measure botulinum neurotoxin serotype A activity using cleavage-sensitive antibodies. J Biomol Screen. 15(1):42–51.
   PubMedGoogle Scholar
• O'Grady NP, Alexander M, Dellinger EP, Gerberding JL, Heard SO, Maki DG, Masur H, McCormick RD, Mermel LA, Pearson ML, et al. 2002. Guidelines for the prevention of intravascular catheter-related infections. Clin Infect Dis. 35(11):1281–1307.
   Web of Science ®Google Scholar
• Pan C, Kumar C, Bohl S, Klingmueller U, Mann M. 2009. Comparative proteomic phenotyping of cell lines and primary cells to assess preservation of cell type-specific functions. Mol Cell Proteomics. 8(3):443–450.
   PubMed Web of Science ®Google Scholar
• Park JB, Simpson LL. 2003. Inhalational poisoning by botulinum toxin and inhalation vaccination with its heavy-chain component. Infect Immun. 71(3):1147–1154.
   PubMed Web of Science ®Google Scholar
• Patel KB, Cai S, Adler M, Singh BK, Parmar VS, Singh BR. 2018. Natural compounds and their analogues as potent antidotes against the most poisonous bacterial toxin. Appl Environ Microbiol. 84(24):1–15. DOI:10.1128/aem.01280-18
   Web of Science ®Google Scholar
• Peck MW. 2009. Biology and genomic analysis of Clostridium botulinum. Adv Microb Physiol. 55:183–265.
   PubMed Web of Science ®Google Scholar
• Pellett S, Tepp WH, Clancy CM, Borodic GE, Johnson EA. 2007. A neuronal cell-based botulinum neurotoxin assay for highly sensitive and specific detection of neutralizing serum antibodies. FEBS Lett. 581(25):4803–4808.
   PubMed Web of Science ®Google Scholar
• Pellett S, Tepp WH, Toth SI, Johnson EA. 2010. Comparison of the primary rat spinal cord cell (RSC) assay and the mouse bioassay for botulinum neurotoxin type A potency determination. J Pharmacol Toxicol Methods. 61(3):304–310.
   PubMed Web of Science ®Google Scholar
• Pellett S, Tepp WH, Bradshaw M, Kalb SR, Dykes JK, Lin G, Nawrocki EM, Pier CL, Barr JR, Maslanka SE, et al. 2016. Purification and characterization of botulinum neurotoxin FA from a genetically modified Clostridium botulinum strain. mSphere. 1(1).DOI:10.1128/msphere.00100-15
   PubMed Web of Science ®Google Scholar
• Pellett S. 2013. Progress in cell based assays for botulinum neurotoxin detection. Curr Top Microbiol Immunol. 364:257–285.
   PubMed Web of Science ®Google Scholar
• Pellett S, Du ZW, Pier CL, Tepp WH, Zhang SC, Johnson EA. 2011. Sensitive and quantitative detection of botulinum neurotoxin in neurons derived from mouse embryonic stem cells. Biochem Biophys Res Commun. 404(1):388–392.
   PubMed Web of Science ®Google Scholar
• Pellett S, Tepp WH, Johnson EA. 2019. Botulinum neurotoxins A, B, C, E, and F preferentially enter cultured human motor neurons compared to other cultured human neuronal populations. FEBS Lett. 593(18):2675–2685.
   PubMedGoogle Scholar
• Peng L, Tepp WH, Johnson EA, Dong M. 2011. Botulinum neurotoxin D uses synaptic vesicle protein SV2 and gangliosides as receptors. PLOS Pathog. 7(3):e1002008.
   PubMed Web of Science ®Google Scholar
• Peng L, Liu H, Ruan H, Tepp WH, Stoothoff WH, Brown RH, Johnson EA, Yao W-D, Zhang S-C, Dong M, et al. 2013. Cytotoxicity of botulinum neurotoxins reveals a direct role of syntaxin 1 and SNAP-25 in neuron survival. Nat Commun. 4:1472.
   PubMed Web of Science ®Google Scholar
• Phillips RW, Abbott D. 2008. High-throughput enzyme-linked immunoabsorbant assay (ELISA) electrochemiluminescent detection of botulinum toxins in foods for food safety and defence purposes. Food Addit Contam Part A Chem Anal Control Expo Risk Assess. 25(9):1084–1088.
   PubMed Web of Science ®Google Scholar
• Pirazzini M, Azarnia Tehran D, Zanetti G, Lista F, Binz T, Shone CC, Rossetto O, Montecucco C. 2015. The thioredoxin reductase–thioredoxin redox system cleaves the interchain disulphide bond of botulinum neurotoxins on the cytosolic surface of synaptic vesicles. Toxicon. 107(Pt A):32–36.
   PubMedGoogle Scholar
• Pirazzini M, Azarnia Tehran D, Leka O, Zanetti G, Rossetto O, Montecucco C. 2016. On the translocation of botulinum and tetanus neurotoxins across the membrane of acidic intracellular compartments. Biochim Biophys Acta. 1858(3):467–474.
   PubMed Web of Science ®Google Scholar
• Pirazzini M, Azarnia Tehran D, Zanetti G, Megighian A, Scorzeto M, Fillo S, Shone CC, Binz T, Rossetto O, Lista F, et al. 2014. Thioredoxin and its reductase are present on synaptic vesicles, and their inhibition prevents the paralysis induced by botulinum neurotoxins. Cell Rep. 8(6):1870–1878.
   PubMed Web of Science ®Google Scholar
• Pirazzini M, Bordin F, Rossetto O, Shone CC, Binz T, Montecucco C. 2013. The thioredoxin reductase-thioredoxin system is involved in the entry of tetanus and botulinum neurotoxins in the cytosol of nerve terminals. FEBS Lett. 587(2):150–155.
   PubMed Web of Science ®Google Scholar
• Purkiss JR, Friis LM, Doward S, Quinn CP. 2001. Clostridium botulinum neurotoxins act with a wide range of potencies on SH-SY5Y human neuroblastoma cells. Neurotoxicology. 22(4):447–453.
   PubMed Web of Science ®Google Scholar
• Rao AK, Sobel J, Chatham-Stephens K, Luquez C. 2021. Clinical guidelines for diagnosis and treatment of botulism, 2021. MMWR Recomm Rep. 70(2):1–30.
   PubMed Web of Science ®Google Scholar
• Rasetti-Escargueil C, Liu Y, Rigsby P, Jones RGA, Sesardic D. 2011. Phrenic nerve-hemidiaphragm as a highly sensitive replacement assay for determination of functional botulinum toxin antibodies. Toxicon. 57(7–8):1008–1016.
   PubMed Web of Science ®Google Scholar
• Ravichandran E, Gong Y, Al Saleem FH, Ancharski DM, Joshi SG, Simpson LL. 2006. An initial assessment of the systemic pharmacokinetics of botulinum toxin. J Pharmacol Exp Ther. 318(3):1343–1351.
   PubMed Web of Science ®Google Scholar
• Ravichandran E, Janardhanan P, Patel K, Riding S, Cai S, Singh BR. 2016. In vivo toxicity and immunological characterization of detoxified recombinant botulinum neurotoxin type A. Pharm Res. 33(3):639–652.
   PubMed Web of Science ®Google Scholar
• Rossetto O, Schiavo G, Montecucco C, Poulain B, Deloye F, Lozzi L, Shone CC. 1994. SNARE motif and neurotoxins. Nature. 372(6505):415–416.
   PubMed Web of Science ®Google Scholar
• Rossetto O, Pirazzini M, Montecucco C. 2014. Botulinum neurotoxins: genetic, structural and mechanistic insights. Nat Rev Microbiol. 12(8):535–549.
   PubMed Web of Science ®Google Scholar
• Rummel A. 2013. Double receptor anchorage of botulinum neurotoxins accounts for their exquisite neurospecificity. Curr Top Microbiol Immunol. 364:61–90.
   PubMed Web of Science ®Google Scholar
• Rummel A, Karnath T, Henke T, Bigalke H, Binz T. 2004. Synaptotagmins I and II act as nerve cell receptors for botulinum neurotoxin G. J Biol Chem. 279(29):30865–30870.
   PubMed Web of Science ®Google Scholar
• Rummel A. 2017. Two feet on the membrane: uptake of Clostridial neurotoxins. Curr Top Microbiol Immunol. 406:1–37.
   PubMed Web of Science ®Google Scholar
• Rummel A, Häfner K, Mahrhold S, Darashchonak N, Holt M, Jahn R, Beermann S, Karnath T, Bigalke H, Binz T, et al. 2009. Botulinum neurotoxins C, E and F bind gangliosides via a conserved binding site prior to stimulation-dependent uptake with botulinum neurotoxin F utilising the three isoforms of SV2 as second receptor. J Neurochem. 110(6):1942–1954.
   PubMed Web of Science ®Google Scholar
• Rust A, Doran C, Hart R, Binz T, Stickings P, Sesardic D, Peden AA, Davletov B. 2017. A cell line for detection of botulinum neurotoxin type B. Front Pharmacol. 8:796.
   PubMed Web of Science ®Google Scholar
• Saini J, Faroni A, Abd Al Samid M, Reid AJ, Lightfoot AP, Mamchaoui K, Mouly V, Butler-Browne G, McPhee JS, Degens H, et al. 2019. Simplified in vitro engineering of neuromuscular junctions between rat embryonic motoneurons and immortalized human skeletal muscle cells. Stem Cells Cloning. 12:1–9.
   PubMed Web of Science ®Google Scholar
• Sakaguchi G. 1982. Clostridium botulinum toxins. Pharmacol Ther. 19(2):165–194.
   PubMed Web of Science ®Google Scholar
• Sakaguchi K, Okuda M, Tanigaito Y, Ohnishi M. 1983. Nasal polyps and appearance of basophilic cells on the mucosal surface of nose. Nihon Jibiinkoka Gakkai Kaiho. 86(1):30–35.
   PubMedGoogle Scholar
• Santhanam N, Kumanchik L, Guo X, Sommerhage F, Cai Y, Jackson M, Martin C, Saad G, McAleer CW, Wang Y, et al. 2018. Stem cell derived phenotypic human neuromuscular junction model for dose response evaluation of therapeutics. Biomaterials. 166:64–78.
   PubMed Web of Science ®Google Scholar
• Scarlatos A, Cadotte AJ, DeMarse TB, Welt BA. 2008. Cortical networks grown on microelectrode arrays as a biosensor for botulinum toxin. J Food Science. 73(3):E129–36.
   PubMed Web of Science ®Google Scholar
• Schantz EJ, Kautter DA. 1978. Standardized Assay for Clostridium botulinum Toxins. J Assoc of Off Anal Chem. 61(1):96–99.
   Google Scholar
• Schenke M, Schjeide BM, Puschel GP, Seeger B. 2020. Analysis of motor neurons differentiated from human induced pluripotent stem cells for the use in cell-based botulinum neurotoxin activity assays. Toxins (Basel). 12(5):276.
   PubMed Web of Science ®Google Scholar
• Schenke M, Prause HC, Bergforth W, Przykopanski A, Rummel A, Klawonn F, Seeger B. 2021. Human-relevant sensitivity of iPSC-derived human motor neurons to BoNT/A1 and B1. Toxins. 13(8):585.
   PubMed Web of Science ®Google Scholar
• Schiavo G, Benfenati F, Poulain B, Rossetto O, Polverino de Laureto P, DasGupta BR, Montecucco C. 1992. Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin. Nature. 359(6398):832–835.
   PubMed Web of Science ®Google Scholar
• Schiavo G, Shone CC, Rossetto O, Alexander FC, Montecucco C. 1993. Botulinum neurotoxin serotype F is a zinc endopeptidase specific for VAMP/synaptobrevin. J Biol Chem. 268(16):11516–11519.
   PubMed Web of Science ®Google Scholar
• Schiavo G, Malizio C, Trimble WS, Polverino de Laureto P, Milan G, Sugiyama H, Johnson EA, Montecucco C. 1994. Botulinum G neurotoxin cleaves VAMP/synaptobrevin at a single Ala-Ala peptide bond. J Biol Chem. 269(32):20213–20216.
   PubMed Web of Science ®Google Scholar
• Schiavo G, Rossetto O, Catsicas S, Polverino de Laureto P, DasGupta BR, Benfenati F, Montecucco C. 1993. Identification of the nerve terminal targets of botulinum neurotoxin serotypes A, D, and E. J Biol Chem. 268(32):23784–23787.
   PubMed Web of Science ®Google Scholar
• Schiavo G, Santucci A, Dasgupta BR, Mehta PP, Jontes J, Benfenati F, Wilson MC, Montecucco C. 1993. Botulinum neurotoxins serotypes A and E cleave SNAP-25 at distinct COOH-terminal peptide bonds. FEBS Lett. 335(1):99–103.
   PubMed Web of Science ®Google Scholar
• Scott AB. 1980. Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. Ophthalmology. 87(10):1044–1049.
   PubMed Web of Science ®Google Scholar
• Scott AB. 1981. Botulinum toxin injection of eye muscles to correct strabismus. Trans Am Ophthalmol Soc. 79:734–770.
   PubMedGoogle Scholar
• Scott AB, Rosenbaum A, Collins CC. 1973. Pharmacologic weakening of extraocular muscles. Invest Ophthalmol. 12(12):924–927.
   PubMedGoogle Scholar
• Sheridan RE. 1998. Gating and permeability of ion channels produced by botulinum toxin types A and E in PC12 cell membranes. Toxicon. 36(5):703–717.
   PubMed Web of Science ®Google Scholar
• Sheridan RE, Smith TJ, Adler M. 2005. Primary cell culture for evaluation of botulinum neurotoxin antagonists. Toxicon. 45(3):377–382.
   PubMed Web of Science ®Google Scholar
• Shone CC, Melling J. 1992. Inhibition of calcium-dependent release of noradrenaline from PC12 cells by botulinum type-A neurotoxin. Long-term effects of the neurotoxin on intact cells. Eur J Biochem. 207(3):1009–1016.
   PubMedGoogle Scholar
• Simpson LL. 2004. Identification of the major steps in botulinum toxin action. Annu Rev Pharmacol Toxicol. 44:167–193.
   PubMed Web of Science ®Google Scholar
• Simpson LL, Rapport MM. 1971. The binding of botulinum toxin to membrane lipids: phospholipids and proteolipid. J Neurochem. 18(9):1761–1767.
   PubMed Web of Science ®Google Scholar
• Singh BR. 2006. Botulinum neurotoxin structure, engineering, and novel cellular trafficking and targeting. Neurotox Res. 9(2–3):73–92.
   PubMed Web of Science ®Google Scholar
• Singh BR, Thirunavukkarasu N, Ghosal K, Ravichandran E, Kukreja R, Cai S, Zhang P, Ray R, Ray P. 2010. Clostridial neurotoxins as a drug delivery vehicle targeting nervous system. Biochimie. 92(9):1252–1259.
   PubMed Web of Science ®Google Scholar
• Smith LDS, Sugiyama H. 1988. Botulism: the organism, its toxins, the disease. Springfield, Ill., USA: Thomas.
   Google Scholar
• Smith TJ, Hill KK, Raphael BH. 2015. Historical and current perspectives on Clostridium botulinum diversity. Res Microbiol. 166(4):290–302.
   PubMed Web of Science ®Google Scholar
• Solomon HM, Lilly T. Jr. 2001. Clostridium botulinum. Bacteriological analytical manual, 8th ed, Revision A, 1998. Chapter 17.
   Google Scholar
• Stahl AM, Ruthel G, Torres-Melendez E, Kenny TA, Panchal RG, Bavari S. 2007. Primary cultures of embryonic chicken neurons for sensitive cell-based assay of botulinum neurotoxin: implications for therapeutic discovery. J Biomol Screen. 12(3):370–377.
   PubMedGoogle Scholar
• Strotmeier J, Gu S, Jutzi S, Mahrhold S, Zhou J, Pich A, Eichner T, Bigalke H, Rummel A, Jin R, et al. 2011. The biological activity of botulinum neurotoxin type C is dependent upon novel types of ganglioside binding sites. Mol Microbiol. 81(1):143–156.
   PubMed Web of Science ®Google Scholar
• Thirunavukkarasusx N, Ghosal KJ, Kukreja R, Zhou Y, Dombkowski A, Cai S, Singh BR. 2011. Microarray analysis of differentially regulated genes in human neuronal and epithelial cell lines upon exposure to type A botulinum neurotoxin. Biochem Biophys Res Commun. 405(4):684–690.
   PubMed Web of Science ®Google Scholar
• Thyagarajan B. 2015. Antidotes to Botulinum Neurotoxin. In: Gopalakrishnakone P, Balali-Mood M, Llewellyn L, Singh BR, editors. Biological toxins and bioterrorism toxinology. Dordrecht: Springer.
   Google Scholar
• Truong DD, Stenner A, Reichel G. 2009. Current clinical applications of botulinum toxin. Curr Pharm Des. 15(31):3671–3680.
   PubMed Web of Science ®Google Scholar
• Tsaioun K, Blaauboer BJ, Hartung T. 2016. Evidence-based absorption, distribution, metabolism, excretion (ADME) and its interplay with alternative toxicity methods. ALTEX. 33(4):343–358.
   PubMedGoogle Scholar
• Tulin EKC, Nakazawa C, Nakamura T, Saito S, Ohzono N, Hiemori K, Nakakita S-I, Tateno H, Tonozuka T, Nishikawa A. 2021. Glycan detecting tools developed from the Clostridium botulinum whole hemagglutinin complex. Sci Rep. 11(1):21973.
   PubMed Web of Science ®Google Scholar
• Vazquez-Cintron EJ, Beske PH, Tenezaca L, Tran BQ, Oyler JM, Glotfelty EJ, Angeles CA, Syngkon A, Mukherjee J, Kalb SR, et al. 2017. Engineering botulinum neurotoxin C1 as a molecular vehicle for intra-neuronal drug delivery. Sci Rep. 7:42923
   PubMed Web of Science ®Google Scholar
• Verderio C, Pozzi D, Pravettoni E, Inverardi F, Schenk U, Coco S, Proux-Gillardeaux V, Galli T, Rossetto O, Frassoni C, et al. 2004. SNAP-25 modulation of calcium dynamics underlies differences in GABAergic and glutamatergic responsiveness to depolarization. Neuron. 41(4):599–610.
   PubMed Web of Science ®Google Scholar
• Wainwright RB, Heyward WL, Middaugh JP, Hatheway CL, Harpster AP, Bender TR. 1988. Food-borne botulism in Alaska, 1947-1985: epidemiology and clinical findings. J Infect Dis. 157(6):1158–1162.
   PubMed Web of Science ®Google Scholar
• Wang D, Krilich J, Pellett S, Baudys J, Tepp WH, Barr JR, Johnson EA, Kalb SR. 2013. Comparison of the catalytic properties of the botulinum neurotoxin subtypes A1 and A5. Biochim Biophys Acta. 1834(12):2722–2728.
   PubMed Web of Science ®Google Scholar
• Wang L, Ringelberg CS, Singh BR. 2020. Dramatic neurological and biological effects by botulinum neurotoxin type A on SH-SY5Y neuroblastoma cells, beyond the blockade of neurotransmitter release. BMC Pharmacol Toxicol. 21(1):66.
   PubMed Web of Science ®Google Scholar
• Wang L, Sun Y, Yang W, Lindo P, Singh BR. 2014. Type A botulinum neurotoxin complex proteins differentially modulate host response of neuronal cells. Toxicon. 82:52–60.
   PubMed Web of Science ®Google Scholar
• Welch MJ, Purkiss JR, Foster KA. 2000. Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicon. 38(2):245–258.
   PubMed Web of Science ®Google Scholar
• Whitemarsh RCM, Tepp WH, Bradshaw M, Lin G, Pier CL, Scherf JM, Johnson EA, Pellett S. 2013. Characterization of botulinum neurotoxin A subtypes 1 through 5 by investigation of activities in mice, in neuronal cell cultures, and in vitro. Infect Immun. 81(10):3894–3902.
   PubMed Web of Science ®Google Scholar
• Whitemarsh RCM, Strathman MJ, Chase LG, Stankewicz C, Tepp WH, Johnson EA, Pellett S. 2012. Novel application of human neurons derived from induced pluripotent stem cells for highly sensitive botulinum neurotoxin detection. Toxicol Sci. 126(2):426–435.
   PubMed Web of Science ®Google Scholar
• Wilder-Kofie TD, Lúquez C, Adler M, Dykes JK, Coleman JD, Maslanka SE. 2011. An alternative in vivo method to refine the mouse bioassay for botulinum toxin detection. Comp Med. 61(3):235–242.
   PubMed Web of Science ®Google Scholar
• Williamson LC, Halpern JL, Montecucco C, Brown JE, Neale EA. 1996. Clostridial neurotoxins and substrate proteolysis in intact neurons: botulinum neurotoxin C acts on synaptosomal-associated protein of 25 kDa. J Biol Chem. 271(13):7694–7699.
   PubMed Web of Science ®Google Scholar
• Xia Y, Whitesides GM. 1998. Soft lithography. Angew Chem Int Ed Engl. 37(5):550–575.
   PubMed Web of Science ®Google Scholar
• Xiao L, Cheng J, Dai J, Zhang D. 2011. Botulinum toxin decreases hyperalgesia and inhibits P2X3 receptor over-expression in sensory neurons induced by ventral root transection in rats. Pain Med. 12(9):1385–1394.
   PubMed Web of Science ®Google Scholar
• Xiao Z, Zhang F, Lin W, Zhang M, Liu Y. 2010. Effect of botulinum toxin type A on transforming growth factor beta1 in fibroblasts derived from hypertrophic scar: a preliminary report. Aesth Plast Surg. 34(4):424–427.
   PubMed Web of Science ®Google Scholar
• Yaguchi T, Nishizaki T. 2010. Extracellular high K + stimulates vesicular glutamate release from astrocytes by activating voltage‐dependent calcium channels. J Cell Physiol. 225(2):512–518.
   PubMed Web of Science ®Google Scholar
• Yiangou Y, Anand U, Otto WR, Sinisi M, Fox M, Birch R, … Anand P. 2011. Increased levels of SV2A botulinum neurotoxin receptor in clinical sensory disorders and functional effects of botulinum toxins A and E in cultured human sensory neurons. J Pain Res. 4:347–355.
   PubMedGoogle Scholar
• Yowler BC, Kensinger RD, Schengrund CL. 2002. Botulinum neurotoxin A activity is dependent upon the presence of specific gangliosides in neuroblastoma cells expressing synaptotagmin I. J Biol Chem. 277(36):32815–32819.
   PubMed Web of Science ®Google Scholar
• Zhang P, Ray R, Singh BR, Li D, Adler M, Ray P. 2009. An efficient drug delivery vehicle for botulism countermeasure. BMC Pharmacol. 9(1):12.
   PubMedGoogle Scholar
• Zhang S, Masuyer G, Zhang J, Shen Y, Lundin D, Henriksson L, Miyashita S-I, Martínez-Carranza M, Dong M, Stenmark P. 2017. Identification and characterization of a novel botulinum neurotoxin. Nat Commun. 8:14130.
   PubMed Web of Science ®Google Scholar
• Zhu H, Wang J, Jacky BPS, Hodges DD, Fernandez-Salas E, inventors; Allergan Inc, assignee. 2010. Cells useful for immuno-based botulinum toxin serotype a activity assays. US-Patent 12/722801.
   Google Scholar